• Find an Expert
  • Contact
  • SearchSearch icon
  • Menu
  • Help
  • Report an issue

Contact


Email

roberto.salgado@unimelb.edu.au

Credentials


Position
Research Assistant
Medicine - Royal Melbourne Hospital
ORCID

0000-0002-1110-3801

Dr Roberto Salgado

Clinical (Senior Lecturer)
The Sir Peter MacCallum Department of Oncology

545 Scholarly works
1 Projects

HIGHLIGHTS

  • 2026

    Journal article

    Clarifying validation terminologies in healthcare
    DOI: 10.1038/s41746-026-02471-2
  • 2026

    Journal article

    Long-term outcomes and treatment response in early-stage invasive lobular carcinoma: insights from a nationwide population-based study
    DOI: 10.1016/j.esmoop.2026.107731
  • 2026

    Journal article

    Incremental prognostic value of an AI-derived histology signature beyond the 21-gene recurrence score: A prospective-retrospective validation in TAILORx.
    DOI: 10.1200/jco.2026.44.16_suppl.554
  • 2026

    Journal article

    Immunity, Age, and Luminal Breast Cancer: Understanding the Holy Trinity
    DOI: 10.1158/1078-0432.CCR-25-4035
  • 2026

    Journal article

    Phase II RAINSPOT: A multicentric open label trial of zolbetuximab-paclitaxel-ramucirumab in second-line setting for CLDN18.2-positive gastro-esophageal adenocarcinoma.
    DOI: 10.1200/jco.2026.44.16_suppl.tps4243
  • 2025

    Research grants (international)

    Validation and Comparison of Computational Pathology-Measured Immune-Biomarkers Using AI-and AI-foundation Models With Patient Level Outcomes in Multiple Randomized Breast Cancer Trials.
  • 2014

    Journal article

    Deciphering clonality in aneuploid breast tumors using SNP array and sequencing data
    DOI: 10.1186/s13059-014-0470-7
Roberto Salgado

RECENT SCHOLARLY WORKS

  • 2026

    Journal article

    Integrating tumor-infiltrating iymphocytes (TILs) in the biomarker landscape of gastroesophageal adenocarcinoma: Going beyond PD-L1.
    DOI: 10.1200/jco.2026.44.16_suppl.4098
  • 2026

    Journal article

    AI-based assessment of tumor-infiltrating lymphocytes (TILs) in patients with triple-negative breast cancer (TNBC) receiving neoadjuvant chemotherapy versus chemo-immunotherapy.
    DOI: 10.1200/JCO.2026.44.16_suppl.e12583
  • 2026

    Journal article

    Prognostic validation of artificial intelligence (AI)–based Stratipath breast risk stratification in TAILORx.
    DOI: 10.1200/JCO.2026.44.16_suppl.555
  • 2026

    Journal article

    Analysis of computational tumor-infiltrating lymphocytes in breast cancer from the results of the TIGER challenge.
    DOI: 10.1038/s41467-026-72956-x
  • 2026

    Journal article

    AI-powered and manual assessment of tumor-infiltrating lymphocytes in early HER2-positive breast cancer in NSABP B-41.
    DOI: 10.1038/s41523-026-00961-w

Acknowledgement of Country

We acknowledge Aboriginal and Torres Strait Islander people as the Traditional Owners of the unceded lands on which we work, learn and live. We pay respect to Elders past, present and future, and acknowledge the importance of Indigenous knowledge in the Academy.

Read about our Indigenous priorities

About us  

Careers at Melbourne  

Safety and respect  

Newsroom  

Contact  

Campus locations  

Phone: 13 MELB ( 13 6352)

International: +61 3 9035 5511


Address:
The University of Melbourne
Grattan Street, Parkville,
Victoria, 3010, Australia

facebookIconlinkedinIconinstagramIcon

Emergency information  |  Disclaimer and copyright  |  Accessibility  |  Privacy

CRICOS number: 00116K     ABN: 84 002 705 224